Home Alzheimer’s Disease Low-Dose Erlotinib Shows Promise in Elderly, Frail Patients with EGFR+ NSCLC

Low-Dose Erlotinib Shows Promise in Elderly, Frail Patients with EGFR+ NSCLC

A multicenter phase II trial published in JAMA Oncology indicated that low-dose erlotinib (Tarceva) appears to be safe and effective in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) and could be a valid treatment option. 

However, more research on the dosing strategy of target-based drugs is warranted according to the researchers, especially in frail patients in the real-world setting. 

“With the increased number of elderly and frail patients with cancer, more patients would receive benefit from this value-based treatment to enhance risk-benefit and cost-benefit ratios,” the authors wrote. “In fact, our low-dose erlotinib therapy could substantially reduce the treatment cost.” 

In this single-arm phase II trial, frail patients were enrolled from 21 Japanese institutions after meeting the inclusion critera. Those who were eligible…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments